Return Address
Date:
Re: Use of Emotions for Persuasion
Dear Sir/ Ma’am,
This letter is to express how Johnson & Johnson (J&J) have used emotions for persuasion purposes in its public service announcement (PSA). The PSA is the organization’s statement on the manufacture of the COVID-19 vaccine as per a CDC Advisory Committee Meeting held on April 23, 2021 (Johnson & Johnson, 2021). The context of the statement comes after scrutiny of fatal side effects surrounding some of the people who have taken the vaccine and the pressure to manufacture more vaccines for the American population.
At the beginning of their statement, J&J state that they have worked with governments, health authorities, and other companies since January 2020 to show that they have worked hard together with other agencies to produce its single-shot vaccine. It reminds the audience that it targeted producing 20 million doses by the end of March 2021, where it succeeded and is in the progress of producing 100 million doses by the end of May as promised. The statement shows that the organization has kept its word in meeting its target. The statement adds that vaccine manufacturing is a complex biological process that encompasses rigorous testing and checking to meet high standards. This part of the statement appeals to the fears about the safety and quality of the vaccine. More so, the statement concludes by assuring the audience that quality and safety continue to be the organization’s top priority.
Delegate your assignment to our experts and they will do the rest.
The statement goes ahead to convince the American citizen that the J&J vaccine is safe and of good quality. It does so by being concise and to the point with factual information, even with the identification of a bad batch that was reported to relevant authorities like the Food and Drug Association (FDA).
Sincerely
Signature
Reference
Johnson & Johnson. (2021). Johnson & Johnson Statement on U.S. COVID-19 Vaccine Manufacturing | Johnson & Johnson . Content Lab U.S. https://www.jnj.com/johnson-johnson-statement-on-u-s-covid-19-vaccine-manufacturing
